ItalyItaly

Rare business

04.11.2010

Rome/Milan – Together with two Italian research institutes, British drug giant Glaxo­SmithKline has begun to develop a therapy for the heriditary immune defect ADA-SCID, which affects only 350 children worldwide. Fondazione Telethon and Fondazione San Raffaele have succeeded with a gene therapy in Phase I and IIa aimed at fixing the stem cells in the patient’s own bone marrow. The partners want to apply the same technique in trials for other rare diseases such as metachromatic leuko­dystrophy or Wiskott-Aldrich syndrome. The cooperation is part of GSK’s strategy to position itself in the ­orphan drug market.

ItalyItaly

12.05.2010

Rome – The Italian GMO-saga continues. After Italy’s Council of State recently overturned a ban on the cultivation of genetically modified MON810 maize, the political empire is striking back. Federal Minister for Agriculture Luca...

ItalyItaly

11.05.2010

Siena – Roche AG is pursuing Alzheimer therapies developed by Siena Biotech. The Swiss pharma company has decided to exercise an option to become the lead party for the further development and commercialisation of certain...

ItalyItaly

28.04.2010

Arcavacata di Rende (Italy) – Researchers from the University of Calabria have established that activation of the nuclear farnesoid X receptor (FXR) can slow the growth of tamoxifen-resistant breast cancer cells. It is the first...

Switzerland, ItalyItaly

02.04.2010

Siena/Basel - Roche has committed to the compounds the Italian outfit Siena Biotech is developing for the use against Alzheimer's disease. The Swiss pharma company will exercise its option to become the lead party for further...

ItalyItaly

10.03.2010

Lainate – Cosmo’s bid for its Italian peer BioXell was successful. At the end of the acceptance period on February 26th, the Italian drug developer traded at the Zurich stock exchange, held 98.96% of all BioXell shares. The offer...

ItalyItaly

08.03.2010

Rome – The Consiglio di Stato, Italy‘s highest court, has overturned the standing ban on the cultivation of genetically modified Mon810 maize. According to the Court, say local papers, Italian farmers do not have to wait with the...

ItalyItaly

01.02.2010

Milan – A court in Milan has given bio­pharmaceutical company MolMed some preliminary breathing space regarding possible patent infringement with MolMed’s cell therapy for the treatment of haematological malignancies (more...)....

ItalyItaly

01.02.2010

Rome – Sigma-Tau S.p.A has achieved promising initial results in a clinical study to evaluate the potential of Zadaxin to increase immune response to the MF59 adjuvanted H1N1 influenza monovalent vaccine Focetria from Novartis....

ItalyItaly

01.02.2010

Lainate – Cosmo Pharmaceuticals has published its public tender offer to acquire all of fellow Italian company Bio­Xell’s outstanding shares. The specialist for optimised generics first offered to buy BioXell for CHF41.3m...

ItalyItaly

19.11.2009

Lainate – Italian company Cosmo Pharmaceuticals SpA has anounced to launch a public tender offer to acquire all outstanding shares of BioXell SpA. According to the pre-announcement, the drug manufacturer’s offer includes a total...

Displaying results 31 to 40 out of 181

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-italy/browse/3/article/rare-business.html

Product of the week

Products

Events

All Events

Current issue

All issues